Continuing the emphasis on preventative care, a new drug may cut the risk of breast cancer recurrence in half.

Breast Cancer Recurrence Is Cut in Half by a Drug
Andrew Pollack
(The New York Times, Apr. 26, 2005)
“A biotechnology cancer drug cuts in half the risk that one type of breast cancer will recur after surgery, the National Cancer Institute and the drug’s manufacturer announced yesterday. Some experts said the results of two clinical trials were so strong that the drug, Genentech’s Herceptin, would soon be added to chemotherapy as a standard part of postsurgical treatment for some women.”